After nearly four years of war and repeated trauma, scores of Ukrainian children are developing severe speech disorders, ...

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program ...

A Brockton teacher helped a 9-year-old student with selective mutism speak at school for the first time. Melody Edward, a teacher at Dessalines S.T.E.A.M. Academy, used the student's doll to build ...

WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to bring transformative ...

- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on ...

-KAIST and UNIST Researchers Develop Shape-Morphing Device to Overcome Pancreatic Tumor Microenvironment Barriers Conventional pancreatic cancer treatments face a critical hurdle due to the dense ...

Selective mutism causes some kids and teens to be too fearful to talk in some situations. Students with selective mutism might be able to speak just fine in comfortable environments, like at home with ...

VS-041 is currently being evaluated in a phase 1c trial in adult patients with heart failure with preserved ejection fraction and elevated serum levels of endotrophin. The Food and Drug Administration ...

Certain statements in this report, including information incorporated by reference, are “forward-looking statements” defined in the Private Securities Litigation Reform Act of 1995 ("PSLRA"). The ...

CHENGDU, China, Sept. 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged ...